ReviewCureus2025
A Systematic Review: Efficacy of Different Intraocular Pressure-Lowering Agents in Black Individuals.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is one of the leading causes of blindness worldwide, with the Black population experiencing an earlier onset and severe form of the disease compared to the White population. Despite the increased prevalence in the Black community, most research pertaining to glaucoma is focused on White patients. The current management guidelines recommend prostaglandin analogues and non-selective beta-adrenergic antagonists as the mainstay treatment, however their comparative efficacy in the Black community has not been thoroughly investigated. This systematic review aims to investigate the efficacy of the various intraocular pressure (IOP) lowering agents used to treat primary open angle glaucoma (POAG) and ocular hypertension (OHT) in Black patients. A systematic review of three randomised controlled trials was conducted to assess the efficacy of IOP-lowering agents specifically in the Black population. The protocol was set prior to the literature search and registered in PROSPERO (CRD420025652374). Databases searched included PubMed, Cochrane Library, Europe PMC and Semantic Scholar. Two independent researchers reviewed the articles and data was extracted from the three eligible articles. Risk of bias was assessed using the Risk of Bias (RoB) 2 tool. Our study found prostaglandin analogues to be highly efficient in the Black community and non-selective beta-adrenergic antagonists to have a lower efficacy in this population. The results align with the current National Institute for Health and Care Excellence (NICE) guidelines recommending prostaglandin analogue as the first-line treatment for POAG and OHT. However, the NICE guidelines recommend non-selective beta-adrenergic antagonists as the second-line treatment, which has a lower efficacy in Black patients. In addition, our study found prostamides to be only slightly less efficient compared to prostaglandin analogues in the Black population. In conclusion, prostaglandin analogues are a suitable first-line IOP-lowering agent in Black patients. Further research is required to investigate a suitable second-line treatment option in this community if patients have any adverse effects or do not tolerate the first-line option or need additional reduction in IOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.